268 related articles for article (PubMed ID: 30726515)
1. Psychopharmacology: neuroimmune signaling in psychiatric disease-developing vaccines against abused drugs using toll-like receptor agonists.
Yang F; Kosten TR
Psychopharmacology (Berl); 2019 Oct; 236(10):2899-2907. PubMed ID: 30726515
[TBL] [Abstract][Full Text] [Related]
2. The Toll-like receptor 5 agonist entolimod suppresses hepatic metastases in a murine model of ocular melanoma via an NK cell-dependent mechanism.
Yang H; Brackett CM; Morales-Tirado VM; Li Z; Zhang Q; Wilson MW; Benjamin C; Harris W; Waller EK; Gudkov AV; Burdelya LG; Grossniklaus HE
Oncotarget; 2016 Jan; 7(3):2936-50. PubMed ID: 26655090
[TBL] [Abstract][Full Text] [Related]
3. TLR5 agonist entolimod reduces the adverse toxicity of TNF while preserving its antitumor effects.
Haderski GJ; Kandar BM; Brackett CM; Toshkov IM; Johnson CP; Paszkiewicz GM; Natarajan V; Gleiberman AS; Gudkov AV; Burdelya LG
PLoS One; 2020; 15(2):e0227940. PubMed ID: 32027657
[TBL] [Abstract][Full Text] [Related]
4. Mobilan: a recombinant adenovirus carrying Toll-like receptor 5 self-activating cassette for cancer immunotherapy.
Mett V; Komarova EA; Greene K; Bespalov I; Brackett C; Gillard B; Gleiberman AS; Toshkov IA; Aygün-Sunar S; Johnson C; Karasik E; Bapardekar-Nair M; Kurnasov OV; Osterman AL; Stanhope-Baker PS; Morrison C; Moser MT; Foster BA; Gudkov AV
Oncogene; 2018 Jan; 37(4):439-449. PubMed ID: 28967901
[TBL] [Abstract][Full Text] [Related]
5. A deimmunized and pharmacologically optimized Toll-like receptor 5 agonist for therapeutic applications.
Mett V; Kurnasov OV; Bespalov IA; Molodtsov I; Brackett CM; Burdelya LG; Purmal AA; Gleiberman AS; Toshkov IA; Burkhart CA; Kogan YN; Andrianova EL; Gudkov AV; Osterman AL
Commun Biol; 2021 Apr; 4(1):466. PubMed ID: 33846531
[TBL] [Abstract][Full Text] [Related]
6. Toll-like receptor-5 agonist Entolimod broadens the therapeutic window of 5-fluorouracil by reducing its toxicity to normal tissues in mice.
Kojouharov BM; Brackett CM; Veith JM; Johnson CP; Gitlin II; Toshkov IA; Gleiberman AS; Gudkov AV; Burdelya LG
Oncotarget; 2014 Feb; 5(3):802-14. PubMed ID: 24583651
[TBL] [Abstract][Full Text] [Related]
7. Toll-like receptor-5 agonist, entolimod, suppresses metastasis and induces immunity by stimulating an NK-dendritic-CD8+ T-cell axis.
Brackett CM; Kojouharov B; Veith J; Greene KF; Burdelya LG; Gollnick SO; Abrams SI; Gudkov AV
Proc Natl Acad Sci U S A; 2016 Feb; 113(7):E874-83. PubMed ID: 26831100
[TBL] [Abstract][Full Text] [Related]
8. TLR5 binding and activation by KMRC011, a flagellin-derived radiation countermeasure.
Song WS; Kim JH; Choi CM; Lee WJ; Yoon SI
Biochem Biophys Res Commun; 2019 Jan; 508(2):570-575. PubMed ID: 30509486
[TBL] [Abstract][Full Text] [Related]
9. The Toll-Like Receptor 5 Agonist Entolimod Mitigates Lethal Acute Radiation Syndrome in Non-Human Primates.
Krivokrysenko VI; Toshkov IA; Gleiberman AS; Krasnov P; Shyshynova I; Bespalov I; Maitra RK; Narizhneva NV; Singh VK; Whitnall MH; Purmal AA; Shakhov AN; Gudkov AV; Feinstein E
PLoS One; 2015; 10(9):e0135388. PubMed ID: 26367124
[TBL] [Abstract][Full Text] [Related]
10. Co-utilization of a TLR5 agonist and nano-formulation of HIV-1 vaccine candidate leads to increased vaccine immunogenicity and decreased immunogenic dose: A preliminary study.
Rostami H; Ebtekar M; Ardestani MS; Yazdi MH; Mahdavi M
Immunol Lett; 2017 Jul; 187():19-26. PubMed ID: 28479111
[TBL] [Abstract][Full Text] [Related]
11. Animal Models and the Development of Vaccines to Treat Substance Use Disorders.
Ohia-Nwoko O; Kosten TA; Haile CN
Int Rev Neurobiol; 2016; 126():263-91. PubMed ID: 27055616
[TBL] [Abstract][Full Text] [Related]
12. Avian influenza virus vaccines containing Toll-like receptors 2 and 5 ligand adjuvants promote protective immune responses in chickens.
St Paul M; Brisbin JT; Barjesteh N; Villaneueva AI; Parvizi P; Read LR; Nagy E; Sharif S
Viral Immunol; 2014 May; 27(4):160-6. PubMed ID: 24797722
[TBL] [Abstract][Full Text] [Related]
13. Indirect Toll-like receptor 5-mediated activation of conventional dendritic cells promotes the mucosal adjuvant activity of flagellin in the respiratory tract.
Fougeron D; Van Maele L; Songhet P; Cayet D; Hot D; Van Rooijen N; Mollenkopf HJ; Hardt WD; Benecke AG; Sirard JC
Vaccine; 2015 Jun; 33(29):3331-41. PubMed ID: 26003491
[TBL] [Abstract][Full Text] [Related]
14. Flagellin enhances tumor-specific CD8⁺ T cell immune responses through TLR5 stimulation in a therapeutic cancer vaccine model.
Nguyen CT; Hong SH; Sin JI; Vu HV; Jeong K; Cho KO; Uematsu S; Akira S; Lee SE; Rhee JH
Vaccine; 2013 Aug; 31(37):3879-87. PubMed ID: 23831323
[TBL] [Abstract][Full Text] [Related]
15. Ethical Implications in Vaccine Pharmacotherapy for Treatment and Prevention of Drug of Abuse Dependence.
Carfora A; Cassandro P; Feola A; La Sala F; Petrella R; Borriello R
J Bioeth Inq; 2018 Mar; 15(1):45-55. PubMed ID: 29350320
[TBL] [Abstract][Full Text] [Related]
16. Mitigation of Radiation-Induced Epithelial Damage by the TLR5 Agonist Entolimod in a Mouse Model of Fractionated Head and Neck Irradiation.
Toshkov IA; Gleiberman AS; Mett VL; Hutson AD; Singh AK; Gudkov AV; Burdelya LG
Radiat Res; 2017 May; 187(5):570-580. PubMed ID: 28323577
[TBL] [Abstract][Full Text] [Related]
17. Cocaine Vaccine Development: Evaluation of Carrier and Adjuvant Combinations That Activate Multiple Toll-Like Receptors.
Kimishima A; Wenthur CJ; Eubanks LM; Sato S; Janda KD
Mol Pharm; 2016 Nov; 13(11):3884-3890. PubMed ID: 27717287
[TBL] [Abstract][Full Text] [Related]
18. Blocking of the TLR5 activation domain hampers protective potential of flagellin DNA vaccine.
Saha S; Takeshita F; Matsuda T; Jounai N; Kobiyama K; Matsumoto T; Sasaki S; Yoshida A; Xin KQ; Klinman DM; Uematsu S; Ishii KJ; Akira S; Okuda K
J Immunol; 2007 Jul; 179(2):1147-54. PubMed ID: 17617608
[TBL] [Abstract][Full Text] [Related]
19. A Clinical Trial of Entolimod a TLR-5 Adjuvant for Vaccines Using Diphtheria or Tetanus as Carrier Proteins.
Kosten TR; Domingo CB; Haile CN; Nielsen DA
Vaccines (Basel); 2022 Sep; 10(10):. PubMed ID: 36298456
[TBL] [Abstract][Full Text] [Related]
20. Implications of central immune signaling caused by drugs of abuse: mechanisms, mediators and new therapeutic approaches for prediction and treatment of drug dependence.
Coller JK; Hutchinson MR
Pharmacol Ther; 2012 May; 134(2):219-45. PubMed ID: 22316499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
